Repositioning Candidates

Repositioning candidates for NAFLD are derived from DrugBank which fall into three categories: therapeutic strategy-associated, target-associated, and indication-associated candidates. For each candidate, detailed properties are extracted from DrugBank, and related strategies, target and NAFLD-associated disease in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3

Search for:

     Peroxisome proliferator-activated receptor alpha
36 records.
Candidate ID Source ID Source Type Compound Type Candidate Name Inclusion Criteria
R0043 DB00132 approved; investigational; nutraceutical small molecule alpha-Linolenic acid Therapeutic strategy associated Details
R0056 DB00159 approved; nutraceutical small molecule Icosapent Therapeutic strategy associated Details
R0112 DB00313 approved; investigational small molecule Valproic acid Therapeutic strategy associated Details
R0117 DB00328 approved; investigational small molecule Indomethacin Therapeutic strategy associated Details
R0197 DB00573 approved small molecule Fenoprofen Target associated Details
R0226 DB00636 approved; investigational small molecule Clofibrate Target associated Details
R0385 DB01050 approved small molecule Ibuprofen Target associated Details
R0413 DB01118 approved; investigational small molecule Amiodarone Target associated Details
R0552 DB01708 approved; investigational; nutraceutical small molecule Prasterone Target associated Details
R0556 DB01890 experimental small molecule N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide Target associated Details
R0560 DB02266 approved small molecule Flufenamic acid Target associated Details
R0570 DB02746 experimental small molecule Phthalic Acid Target associated Details
R0574 DB03017 approved; experimental small molecule Lauric acid Target associated Details
R0579 DB03193 approved; experimental small molecule Stearic acid Target associated Details
R0594 DB03796 approved small molecule Palmitic Acid Target associated Details
R0597 DB04224 approved; investigational; vet_approved small molecule Oleic Acid Target associated Details
R0605 DB04519 investigational small molecule Caprylic acid Target associated Details
R0607 DB04557 experimental small molecule Arachidonic Acid Target associated Details
R0664 DB04971 investigational small molecule Reglitazar Target associated Details
R0789 DB05416 investigational small molecule Cardarine Target associated Details
R1034 DB06510 investigational small molecule Muraglitazar Target associated Details
R1038 DB06521 investigational small molecule Ertiprotafib Target associated Details
R1041 DB06533 investigational small molecule Ragaglitazar Target associated Details
R1042 DB06536 investigational small molecule Tesaglitazar Target associated Details
R1118 DB07215 investigational small molecule GW-590735 Target associated Details
R1127 DB07724 experimental small molecule Indeglitazar Target associated Details
R1140 DB08231 experimental small molecule Myristic acid Target associated Details
R1187 DB08915 investigational small molecule Aleglitazar Target associated Details
R1192 DB09006 experimental small molecule Clinofibrate Target associated Details
R1209 DB09064 approved; investigational small molecule Ciprofibrate Target associated Details
R1244 DB09213 approved; investigational small molecule Dexibuprofen Therapeutic strategy associated Details
R1309 DB09422 approved biotech Soybean oil Therapeutic strategy associated Details
R1383 DB11605 approved small molecule Myrrh Therapeutic strategy associated Details
R1427 DB12007 experimental small molecule Isoflavone Therapeutic strategy associated Details
R1470 DB12961 investigational small molecule Leukotriene B4 Target associated Details
R1497 DB13873 approved small molecule Fenofibric acid Target associated Details